Comparison of the efficacy and safety of a new recombinant human follicle‐stimulating hormone (DA‐3801) with follitropin‐α (Gonal‐F^®) in women undergoing controlled ovarian hyperstimulation for assisted reproductive technology

Abstract

The results of this study demonstrate that DA-3801 is not inferior to follitropin-alpha in terms of its efficacy and safety in women undergoing COH for ART.

Increased responsiveness may be associated with tripronuclear embryos in both conventional in vitro fertilization and intracytoplasmic sperm injection cycles using gonadotropin-releasing hormone agonist long protocols: A self-matched observational study

“…Ovarian stimulation was performed as previously described 13,14 . Briefly, triptorelin (Decapeptyl, 0.1 mg/day; Ferring, Malmo, Sweden) was started in the mid‐luteal phase of the previous cycle.…”

Human Recombinant FSH and Its Biosimilars: Clinical Efficacy, Safety, and Cost-Effectiveness in Controlled Ovarian Stimulation for In Vitro Fertilization

“…The safety and efficacy of the follitropin alpha biosimilar DA-3801 was investigated by Moon et al [ 69 ] in a phase III, multicenter, randomized, non-inferiority trial (NCT01820728) comprising 97 women randomized to receive COS using DA-3801 ( n = 49) or Gonal-F ® ( n = 48) ( Table 1 ). The number of retrieved oocytes was set as primary endpoint, whereas the total FSH dose, the length of stimulation, the serum estradiol levels on the day of oocyte maturation trigger, and the fertilization, implantation and pregnancy rates were considered as secondary endpoints.…”

Symmetry in number of retrieved oocytes between two ovaries: a possible predictor ofin vitrofertilization outcome

“…COS was done as previously described [11][12][13]. Triptorelin (Decapeptyl 1 , 0.1 mg/day; Ferring, Malmo, Sweden) was started in the mid-luteal phase of the previous cycle in the GnRH agonist long protocol.…”